A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: Clinical tolerance and effect on activation markers and cytokines

AIDS Research and Human Retroviruses

Volumn 13, Issue 18, 1997, Pages 1625-1631

  Marriott, J B ^a   Cookson, S ^a   Carlin, E ^a   Youle, M ^a   Hawkins, D A ^a   Nelson, M ^a   Pearson, M ^a   Vaughan, A N ^a   Gazzard, B ^a   Dalgleish, A G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; CD4 ANTIGEN; CD8 ANTIGEN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE;

ABDOMINAL PAIN; ANOREXIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; LYMPHOCYTE COUNT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0031459383     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1997.13.1625     Document Type: Article

References (20)